BioSpace News Archive

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2022, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2022.

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Stevanato Group S.p.A. announced that it will issue financial results for the third quarter of 2022 on Tuesday, November 8, 2022, at 6:30 a.m. Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. on Tuesday, November 8, 2022 to discuss financial results for the third quarter.

Medpace Holdings, Inc. announced financial results for the third quarter ended September 30, 2022.

Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD).

Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time.

Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022.

Cingulate Inc. announced it has executed a Master Services Agreement with Societal CDMO, Inc., a bi-coastal contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.

Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share.

Palatin Technologies, Inc. (NYSE American: PTN) today announced that John Dodd, Ph.D. presented the poster “Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal Inflammatory Diseases” at the American College of Gastroenterology annual meeting in Charlotte, North Carolina.